.png)
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion - Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion: risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion
Cabazitaxel Accord 20 mg/mL concentrate for solution for infusion:
risk of medication errors and mix-up with Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion.
Summary
- There is a risk of medication errors due to the presence on the market of different cabazitaxel presentations:
- Cabazitaxel Accord (20 mg/mL) concentrate for solution for infusion requires a single-step dilution process;
- Jevtana (60 mg/1.5 mL) concentrate and solvent for solution for infusion requires a two-step dilution process.
- Before the final dilution step either in glucose solution or sodium chloride solution for infusion, the concentration of cabazitaxel is:
- 20 mg/ml for Cabazitaxel Accord
- 10 mg/ml for Jevtana
- A mix-up between the products may lead to medication errors resulting in either overdosing with potentially fatal outcome, or underdosing with reduction of therapeutic effect (see background section below).
- Always check carefully which product is being used and the dilution instructions to ensure that the patient receives the correct dose of cabazitaxel.
Published on: 16 June 2021